Minerva Neurosciences Appoints Dr. Gail M. Farfel Amid Pivotal Phase 3 Trial for Radiprodil

Neurvati Neurosciences Welcomes Dr. Gail M. Farfel to Board Amid Pivotal Trial for Neurodevelopmental Disorders

Neurvati Neurosciences, a clinical-stage biotechnology company dedicated to developing therapies for neurological and psychiatric disorders, announces the appointment of Dr. Gail M. Farfel to its board of directors. This strategic move coincides with Neurvati's upcoming Phase 3 trial for radiprodil, aimed at treating GRIN-related neurodevelopmental disorders (GRIN-NDD). Deborah Dunsire, MD, the chairwoman of both Neurvati and GRIN Therapeutics, highlights that Dr. Farfel's extensive experience in neuroscience research—spanning over three decades—will be crucial as the company seeks to advance its innovative therapies.

Dr. Farfel brings a wealth of knowledge to Neurvati, having held leadership roles at prominent organizations including Zogenix, Novartis, and Pfizer. Her previous experience as CEO of ProMIS Neurosciences positions her as a seasoned professional in the field. With over 50 scientific publications in neuropsychopharmacology, Dr. Farfel's expertise aligns well with Neurvati's mission to expedite the development of novel treatments for serious neurological conditions. Her academic credentials, which include a Bachelor's degree in biochemistry from the University of Virginia and a PhD from the University of Chicago, further solidify her role as a leading figure in neuroscience.

The appointment of Dr. Farfel comes at a pivotal time for Neurvati, following a successful Series D financing and a licensing agreement with Angelini Pharma. This partnership enhances Neurvati's global reach and supports its goal of delivering first-in-class therapies to individuals affected by GRIN-NDD and other serious neurodevelopmental disorders. Dr. Farfel expresses her eagerness to contribute to the company’s mission, emphasizing the importance of collaboration and innovation in the pursuit of effective treatments for patients in need.

In addition to Dr. Farfel's appointment, Neurvati's ongoing Phase 3 trial for radiprodil represents a critical milestone for the company. As it moves forward, the insights and leadership of seasoned professionals like Dr. Farfel are expected to play a significant role in navigating the complexities of clinical development and regulatory pathways. The collaboration with GRIN Therapeutics further underscores Neurvati's commitment to addressing the challenges in treating neurodevelopmental disorders, marking a significant step toward improving patient outcomes.

As Neurvati Neurosciences embarks on this promising trajectory, the integration of Dr. Farfel into the board not only reinforces its commitment to pioneering neuroscience therapies but also exemplifies a proactive approach to addressing the pressing needs within the field of neurodevelopmental disorders.